Combining Beta Interferon and Atorvastatin May Increase Disease Activity in Multiple Sclerosis
Neurol 71:1390-1395,1386, Birnbaum,G.,et al, 2008
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008
Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly
Arch Neurol 65:1509-1517, Aizenstein,H.J.,et al, 2008
Primary Central Nervous System Vasculitis with Prominent Leptomeningeal Enhancement
Arthritis Rheum:58:595-603, Salvarani, C.,et al, 2008
Neonatal Diagnosis and Treatment of Menkes Disease
NEJM 358:605-614, Kaler, S.G.,et al, 2008
Seizures on Hearing the Alarm Clock
Lancet 370:2172, Vollmar,C.,et al, 2007
Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report
Neurol 68:977-984, Goodin,D.S.,et al, 2007
Clinical Update:Diagnosis and Treatment of Essential Tremor
Lancet 369:1152-1154, Benito-Leon,J&Louis,E.D., 2007
Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007
Effect of Early Verus Delayed Interferon Beta-1b Treatment on Disability After a First Clinical Event Suggestive of Multiple Sclerosis: A 3-Year Follow-Up Analysis of the BENEFIT Study
Lancet 370:389-397, Kappos,L.,et al, 2007
Imaging of Amyloid Burden and Distribution in Cerebral Amyloid Angiopathy
Ann Neurol 62:229-234, Johnson,K.A.,et al, 2007
Mangnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study: Integrated 2-Year Results
Arch Neurol 64:1292-1298, Barkhof,F.,et al, 2007
Disease-Modifying Therapies for Alzheimer Disease: Challenges to Early Intervention
Neurol 69:1622-1634, Cummings,J.L.,et al, 2007
Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 69:1552-1553, Sorenson,P.S. &Bertolotto,A., 2007
How Effective Are Disease-Modifying Drugs in Delaying Progression in Relapsing-Onset MS?
Neurol 69:1498-1507, Brown,M.G.,et al, 2007
Course of Cerebral Amyloid Angiopathy-Related Inflammation
Neurol 68:1411-1416, Kinnecom,C.,et al, 2007
Multiple Diagnostic Tests Are Needed to Assess Multiple Causes of Dementia
Arch Neurol 63:144-146,146, Rikkert,M.G.M.O.,et al, 2006
Safety and Tolerability of Interferon Beta-1b in Pediatric Multiple Sclerosis
Neurol 66:472-476, Banwell,B.,et al, 2006
Left Insular Stroke is Associated with Adverse Cardiac Outcome
Neurol 66:477-483, Laowattana,S.,et al, 2006
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
IM Interferon B-1a Delays Definite Multiple Sclerosis 5 Years After a First Demyelinating Event
Neurol 66:678-684, CHAMPIONS Study Group, 2006
Syncope and Falls Due to Timolol Eye Drops
BMJ 332:960-961, Mller,M.E.,et al, 2006
Interferon beta-1a Treatment in Childhood and Juvenile-Onset Multiple Sclerosis
Neurol 67:511-513, Tenembaum,S.N. &Segura,M.J., 2006
Treatment With Interferon beta-1b Delays Conversion to Clinically Definite and McDonald MS in Patients With Clinically Isolated Syndromes
Neurol 67:1242-1249, Kappos,L.,et al, 2006
PET of Brain Amyloid and Tau in Mild Cognitive Impairment
NEJM 355:2652-2663, Small,G.W.,et al, 2006
Verapamil Induced Gingival Enlargement in Cluster Headache
JNNP 76:124-127, Matharu,M.S.,et al, 2005
Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005
Neurocardiogenic Syncope
NEJM 352:1004-1010, Grubb, B.P., 2005
FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005
Enhanced Benefit of Increasing Interferon Beta-1a Dose and Frequency in Relapsing Multiple Sclerosis
Arch Neurol 62:785-792, Schwid,S.R.,et al, 2005
Practice Parameter:Therapies for Essential Tremor
Neurol 64:2008-2020, Zesiewicz,T.A.,et al, 2005
Neutralizing Anti-IFN-B Antibodies
Neurol 65:6-8, Giovannoni,G.&Goodman,A., 2005
Life-Threatening Acute Pancreatitis Associated with Interferon Beta-1a Treatment in Multiple Sclerosis
Neurol 65:170-171, Midgard,R.,et al, 2005
Polyneuropathy Associated with Interferon Beta Treatment in Patients with Multiple Sclerosis
Neurol 65:456-458, Ekstein,D.,et al, 2005
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005
Pregnancy Outcomes During Treatment with Interferon Beta-1a in Patients with Multiple Sclerosis
Neurol 65:802-806, Sandberg-Wollheim,M.,et al, 2005
The Reproductive Effects of Beta Interferon Therapy in Pregnancy, A longitudinal Cohort
Neurol 65:807-811,788, Boskovic,R.,et al, 2005
Efficacy and Safety of Cholesterol-Lowering Treatment: Prospective Meta-Analysis of Data from 90056 Participants in 14 Randomised Trials of Statins
Lancet 366:1267-1278, Cholesterol Treatment Trialists (CTT) Collaborators, 2005
Tetraparesis Associated with Colchicine is Probably Due to Inhibition by Verapamil of the P-glycoprotein Efflux Pump in the Blood-Brain Barrier
BMJ 331:513, Troger,U.,et al, 2005
Liver Injury Associated with the B-Interferons for MS
Neurol 62:628-631, Tremlett,H.L.,et al, 2004
Effects of Cholesterol-lowering with Simvastatin on Stroke and Other Major Vascular Events in 20 536 People with Cerebrovascular Disease or Other High-Risk Conditions
Lancet 363:757-767, Heart Protection Study Collaborative Group, 2004
Interferon Beta-1a for Brain Tissue Loss in Patients at Presentation with Syndromes Suggestive of Multiple Sclerosis: A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 364:1489-1496,1463, Filippi,M.,et al, 2004
Interferon beta-1b in Secondary Progressive MS
Neurol 63:1779-1787,1768, Kappos,L.,et al, 2004
Interferon beta-1b in Secondary Progressive MS
Neurol 63:1788-1795,1768, The North American Study Group on Interferon beta-, 2004
MR Spectroscopy in the Diagnosis of Cerebral Amyloid Angiopathy Presenting as a Brain Tumor
AJNR 25:1705-1708, Safriel,Y.,et al, 2004
Clinical Manifestations of Cerebral Amyloid Angiopathy-Related Inflammation
Ann Neurol 55:250-256, Eng,J.A.,et al, 2004
Validation of Diagnositc Magnetic Resonance Imaging Criteria for Multiple Sclerosis and Response to Interferon B1a
Ann Neurol 53:718-724, Barkhof,F.,et al, 2003
Clinical Importance of Neutralising Antibodies Against Interferon Beta in Patients with Relapsing-Remitting Multiple Sclerosis
Lancet 362:1184-1191, Sorensen,P.S.,et al, 2003
Treatment of Sporadic Hemiplegic Migraine with Calcium-Channel Blocker Verapamil
Neurol 60:120-121, Yu,W. &Horowitz,S.H., 2003
Interferons in Relapsing Remitting Multiple Sclerosis: A Systematic Review
Lancet 361:545-552, Filippini,G.,et al, 2003